ArticleJTO clinical and research reports2024

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.

Jie Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.